Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, single‐arm, Japanese phase 2 study was conducted to investiga...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Takahashi, Masato, Masuda, Norikazu, Nishimura, Reiki, Inoue, Kenichi, Ohno, Shinji, Iwata, Hiroji, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Toi, Masakazu
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367628/
https://ncbi.nlm.nih.gov/pubmed/32420697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3091
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars